Resistant Starch
RS2/RS3/RS4
Fermentable starch that resists small-intestine digestion, feeds butyrate-producing gut bacteria, and modestly improves fasting glucose and insulin sensitivity.
Evidence tier
Moderate
Research weight
Citations
11 verified / 11
Classification
Prebiotics & Fibers
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Resistant Starch?
Resistant Starch (RS2/RS3/RS4) is a prebiotic fiber used for acts as a prebiotic: increases bifidobacterium and ruminococcus bromii and raises colonic short-chain fatty acids, especially butyrate, a key fuel for colon cells. NutriDex grades the human evidence as Moderate. Resistant starch (RS) is starch that escapes digestion in the small intestine and is fermented in the colon, where it acts as a prebiotic. The main dietary/supplement forms are RS2 (raw/native granular starch such as high-amylose maize "Hi-maize" and green/unripe banana), RS3 (retrograded starch formed when cooked starchy foods like potatoes, rice and pasta are cooled), and RS4 (chemically modified starches). Randomized trials and meta-analyses most consistently show that RS shifts the microbiome (notably increasing Bifidobacterium and Ruminococcus bromii) and raises colonic short-chain fatty acids, especially butyrate, and modestly lowers fasting glucose and fasting insulin while improving insulin sensitivity; effects on HbA1c and blood lipids are smaller and inconsistent. A landmark long-term trial (CAPP2) found 30 g/day RS for up to 4 years did not reduce colorectal cancer in Lynch syndrome but roughly halved non-colorectal (especially upper-GI) cancers over 10-20 years follow-up, an intriguing but condition-specific finding. Overall the evidence is moderate: real metabolic and microbiome signals, but heterogeneous results and modest effect sizes.
Purported Benefits
✓Acts as a prebiotic: increases Bifidobacterium and Ruminococcus bromii and raises colonic short-chain fatty acids, especially butyrate, a key fuel for colon cells
✓Modestly lowers fasting plasma glucose and fasting insulin and improves insulin sensitivity (HOMA), with larger effects at higher doses (>28 g/day) and in RS2
✓May support weight management: an 8-week crossover RCT of 40 g/day RS2 produced ~2.8 kg weight loss and improved insulin resistance versus control starch
✓Improves stool frequency and laxation: RS3 increased bowel movements and beneficial bacteria in adults with chronic constipation
✓May lower fasting triglycerides and LDL cholesterol in some analyses, though lipid effects are smaller and less consistent than glycemic effects
✓In Lynch syndrome, 30 g/day for up to 4 years was associated with fewer non-colorectal (notably upper-GI) cancers over long-term follow-up, though it did not reduce colorectal cancer
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Prebiotic: raises Bifidobacterium & colonic SCFA/butyrateConsistent across RCTs/systematic review for microbiome and fecal SCFA shifts, though SCFA rise modest and not universal. | Moderate | ↑ benefit · moderate | 3 |
| Lowers fasting glucose & improves insulin sensitivityMeta-analyses show small fasting-glucose drop (-0.09 mmol/L), larger >28 g/day and with RS2; high heterogeneity, no HbA1c effect. | Moderate | ↑ benefit · small | 3 |
| Weight loss / reduced insulin resistanceSingle 8-week crossover RCT (n=37) saw ~2.8 kg loss at 40 g/day RS2; promising but one trial, needs replication. | Preliminary | ↑ benefit · moderate | 1 |
| Improves stool frequency in constipationOne 12-week RCT of 9 g/day RS3 raised bowel-movement frequency in chronically constipated adults vs placebo. | Preliminary | ↑ benefit · moderate | 1 |
| Lowers LDL cholesterolOne meta-analysis in overweight/obese saw LDL reduction; lipid effects smaller and less consistent than glycemic ones. | Preliminary | ↑ benefit · small | 1 |
| Reduces colorectal cancer (Lynch syndrome)CAPP2 RCT: 30 g/day for 4 yr did NOT cut colorectal cancer (HR 0.95), though non-CRC/upper-GI cancers roughly halved. | Moderate | — no effect · negligible | 1 |
Dosing & Compounds
Typical Dose
Most RCTs use 15-40 g/day of resistant starch, commonly 20-30 g/day of an RS2 product (e.g. high-amylose maize or raw potato starch) mixed into cold food or water; glycemic and SCFA benefits tend to be larger above ~28 g/day. Raw potato starch and Hi-maize are not heated (heat gelatinizes RS2 and destroys the resistant fraction). Start low (~5-10 g/day) and increase gradually over 1-2 weeks to limit gas.
Active Compounds
Safety & Cautions
Generally well tolerated; because RS is fully fermentable it is a high-FODMAP-style gas producer and the main side effects are flatulence, bloating, and mild abdominal discomfort, which are dose-dependent and usually improve with gradual escalation. Tolerability reviews find doses of 20-40 g/day are usually acceptable, but bloating and dropouts increase around 45 g/day and some individuals react at lower doses. People with IBS or other functional gut disorders may experience more gas and should titrate slowly. Like other fibers, large doses taken with medications can slow or reduce drug absorption, so separate from medications by a few hours; people with diabetes on glucose-lowering drugs should monitor blood sugar as RS can enhance glycemic-lowering effects. Unlike viscous bulk-forming fibers (psyllium, glucomannan/konjac), RS powders do not form a choking gel, but should still be taken with adequate fluid. The cancer-prevention findings apply specifically to Lynch syndrome and should not be generalized; discuss with a clinician if you have a hereditary cancer syndrome, are pregnant or breastfeeding, or have a GI disorder. Educational only — always check with your doctor or pharmacist before combining Resistant Starch with any medicine.
Key Studies ★ 11 studies
Systematic review
Isyrofi 2026
✓ PubMed
Clinical and mechanistic evidence on metabolic effects of oat β-glucan, rice bran, and unripe banana flour: a systematic review with mechanism-informed synthesis
Systematic review and meta-analysis of RCTs
Yuan et al. 2023 (Front Nutr)
✓ Full text
In type 2 diabetes/prediabetes, RS1 and RS2 lowered postprandial glucose and RS2 improved fasting glucose and insulin, while RS3/RS4 showed weaker or inconsistent glycemic effects across pooled RCTs.
Systematic review and meta-analysis of RCTs
Bergeron et al. 2021 (Br J Nutr)
✓ Source
Meta-analysis of RCTs found resistant starch significantly lowered fasting plasma glucose (ES -0.09 mmol/L; 95% CI -0.13 to -0.04) versus digestible starch, with larger effects at doses >28 g/day, but no significant effect on HbA1c (high heterogeneity).
Systematic review of RCTs
Bendiks et al. 2022 (Am J Clin Nutr)
✓ PubMed
Across 39 RCTs (2,263 participants), resistant starch supplementation was generally well tolerated and increased fecal SCFAs in most studies, with RS2 at 20-40 g/day most common; bloating and dropouts rose around 45 g/day.
Systematic review and meta-analysis of RCTs
Halajzadeh et al. 2019 (Nutr Diabetes)
✓ PubMed
In overweight/obese adults, resistant starch supplementation significantly reduced fasting insulin, HbA1c and LDL cholesterol and improved insulin sensitivity (HOMA-S%) versus control.
Randomized crossover RCT
Li et al. 2024 (Nat Metab)
✓ Full text
In a randomized crossover trial (n=37), 8 weeks of 40 g/day resistant starch produced ~2.8 kg weight loss and improved insulin resistance, with increased Bifidobacterium adolescentis and an altered bile-acid profile.
Randomized double-blind placebo-controlled trial
Klinsanitchkul et al. 2024 (Sci Rep)
✓ PubMed
In Thai adults with chronic constipation, 9 g/day RS3 for 12 weeks increased stool frequency (most subjects reaching >=4 BMs/week) and enriched beneficial bacteria (Bifidobacterium, Prevotella, Akkermansia) versus placebo.
Long-term follow-up of double-blind RCT
Mathers et al. 2022 (Cancer Prev Res, CAPP2)
✓ Full text
In Lynch syndrome, 30 g/day resistant starch for up to 4 years did not reduce colorectal cancer (HR 0.95) but roughly halved non-colorectal Lynch cancers (27 vs 48; HR 0.54), with benefit for upper-GI cancers persisting ~10 years post-intervention.
Randomized placebo-controlled trial
Alfa et al. 2017 (Anaerobe, MSPrebiotic)
✓ PubMed
A digestion-resistant potato starch significantly increased fecal Bifidobacterium versus placebo in mid-age and elderly adults, with a small but significant rise in stool butyrate in older participants.
Review
He 2026
✓ PubMed
Review of resistant-starch delivery-system design, from material fundamentals to colon-targeted applications.
Review
Isin 2026
✓ PubMed
Review of sprouting in gluten-free foods and its effects on glycemic response and antioxidant activity.